Table 1.
| Reference | Country | Date published | Total Ninfants tested | N born via cesarean | N born preterm | N PCR-infectedinfants | Numberof timesswabbed | Antibody differences | Infected infant symptoms | Infant outcomes | Maternal severity | N Apgarscore <7 at 5 min | Feeding | Mother-infantisolation | Early bathing | Latest follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhu et al.83 | China | 2/10/20 | 10 | 7 | 6 | 0 | 1 | NR | Mild | 0 | Presumed formula | Yes | NR | DOL14 | ||
| Liu, Wang et al.82 | China | 2/25/20 | 3 | 2 | 0 | 0 | 1 | NR | Mild | 0 | Formula | Yes | Yes | DOL1 | ||
| Wang, Zhou et al.57 | China | 2/28/20 | 1 | 1 | 1 | 0 | 3 | NR | Severe | 0 | Formula | Yes | NR | DOL20 | ||
| Liu, Chen et al.84 | China | 3/4/20 | 13 | 10 | 6 | 0 | NR | NR | Mild to moderate | 0 | NR | NR | NR | NR* | ||
| Li, Zhao et al.60 | China | 3/5/20 | 1 | 1 | 1 | 0 | 7 | NR | Mild | NR | NR | NR | NR | DOL2 | ||
| Chen, Guo et al.53 | China | 3/7/20 | 9 | 9 | 4 | 0 | 1 | NR | Mild | 0 | NR | NR | NR | NR* | ||
| Zhang et al.61 | China | 3/7/20 | 10 | 10 | NR | 0 | 1 | NR | Mild to severe | 0 | NR | NR | NR | NR* | ||
| Wang, Guo et al.40 | China | 3/12/20 | 1 | 1 | 0 | 1 | 1 | NR | Thickened lung texture | Recovered in 2 weeks | Mild | 0 | Formula | Yes | NR | DOL15 |
| Chen, Peng et al.37 | China | 3/16/20 | 4 | 3 | 0 | 0 | 1 | NR | Mild to severe | 0 | Formula | Yes | NR | NR* | ||
| Chen, Zhang et al.74 | China | 3/16/20 | 17 | 17 | 3 | 0 | 2 | NR | Mild to moderate | 0 | Presumed formula | Yes | Yes | DOL7 | ||
| Fan et al.56 | China | 3/17/20 | 2 | 2 | 1 | 0 | 1 | NR | Mild | 0 | Presumed formula | Yes | NR | DOL20 | ||
| Liu, Li et al.85 | China | 3/18/20 | 11 | 10 | NR | 0 | NR | NR | Mild | 0 | NR | NR | NR | NR* | ||
| Yu et al.41 | China | 3/24/20 | 3 | 3 | 0 | 1 | 1 | NR | Mild pulmonary infection | Recovered in 2 wks | Mild | 0 | NR | NR | NR | DOL28 |
| Zambrano et al.86 | Honduras | 3/25/20 | 1 | 0 | 1 | 0 | 1 | NR | Mild | NR | NR | NR | NR | DOL14 | ||
| Dong et al.48 | China | 3/26/20 | 1 | 1 | 0 | 0 | 5 | ↑IgG, ↑IgM | 0 | Presumed formula | Yes | NR | DOL16 | |||
| Liao et al.55 | China | 3/26/20 | 1 | 1 | 1 | 0 | 1 | NR | Mild | NR | NR | NR | NR | NR* | ||
| Zeng, Xia et al.33 | China | 3/26/20 | 33 | 26 | 4 | 3 | 3 | NR | Pneumonia, lethargy, fever, SOB | Recovered in 1-2 wks | Mild | 1 | Presumed formula | Yes | NR | DOL7 |
| Zeng, Xu et al.47 | China | 3/26/20 | 6 | 6 | NR | 0 | 1 | ↑ IgG (n=5), ↑IgM (n=2) | 0 | Presumed formula | Yes | NR | NR* | |||
| Chen, Liao et al.87 | China | 3/28/20 | 5 | 2 | 0 | 0 | 1 | NR | Mild | 0 | Formula | Yes | NR | NR* | ||
| Li, Han et al.88 | China | 3/30/20 | 3 | 3 | 0 | 0 | 2 | NR | Mild | 0 | NR | NR | NR | DOL14 | ||
| Zhang, Yu et al.61 | China | 4/8/20 | 4 | 4 | 0 | 4 | NR | NR | SOB, fever, cough | Recovered in 2-4 wks | Mild | NR | Formula (n=3), BF (n=1) | Yes (n=2) | NR | ~2 wks-1 mo |
| Schnettler, Ahwel, & Suhag89 | U.S.(OH) | 4/14/20 | 1 | 1 | 1 | 0 | 2 | NR | Severe | NR | Presumed formula | Yes | NR | DOL9 | ||
| Carosso et al., 202046 | Italy | 4/14/20 | 1 | 0 | 0 | 0 | 2 | ↑IgG | 0 | NR | NR | NR | NR* | |||
| Lowe & Bopp11 | Australia | 4/15/20 | 1 | 0 | 0 | 0 | 1 | NR | Mild | 0 | BF | No | NR | DOL10 | ||
| Chen, Li et al.59 | China | 4/17/20 | 8 | NR | NR | 0 | 1 | NR | NR | NR | NR | NR | NR | NR* | ||
| Zamaniyan et al.90 | Iran | 4/17/20 | 1 | 1 | 1 | 1 | 4 | NR | Fever | Recovered in 1 wk | Critical | 0 | Formula | Yes | NR | DOL7 |
| Alzamora et al.42 | Peru | 4/18/20 | 1 | 1 | 1 | 1 | 2 | Tested and neg | Mild respiratory distress, cough | Recovered, time NR | Severe | 0 | Formula | Yes | NR | DOL6 |
| Lyra et al.91 | Portugal | 4/20/20 | 1 | 1 | 0 | 0 | 3 | NR | Mild | 0 | Formula | Yes | NR | DOL7 | ||
| Yan et al.29 | China | 4/23/20 | 86 | 85 | 20 | 0 | 1 | NR | Mild to critical | 0 | NR | NR | NR | NR* | ||
| Kelly et al.34 | U.S. (MO) | 4/23/20 | 1 | 1 | 1 | 0 | 1 | NR | Critical | 1 | NR | NR | NR | NR, until publication | ||
| Sharma et al.10 | India | 4/23/20 | 1 | 1 | 0 | 0 | 1 | NR | Asx | NR | BF | No | NR | NR* | ||
| Hu et al.43 | China | 4/24/20 | 7 | 6 | 0 | 1 | NR | NR | None | No sx | Mild | 0 | Presumed formula | Yes | NR | DOL14 |
| Hantoushzadeh et al.36 | Iran | 4/24/20 | 6 | 6 | 5 | 1 | 1-2 | NR | Pneumonia | Intubated but stable, time NR | Critical | 0 | NR | NR | NR | 1 mo |
| Lu et al.92 | China | 4/24/20 | 1 | 1 | 0 | 0 | 3 | NR | Asx | 0 | Formula | Yes | NR | DOL14 | ||
| Vintzileos et al.93 | U.S. (NY) | 4/25/20 | 29 | NR | NR | 0 | 1 | NR | Two-thirds asx | NR | NR | NR | NR | NR* | ||
| Ferrazzi et al.8 | Italy | 4/27/20 | 42 | 18 | 12 | 2 | NR | NR | None | No sx | Mild to moderate | 2 | BF in asx & mild sx mothers | NR | NR | NR, until discharge |
| Buonsenso et al.44 | Italy | 5/2/20 | 2 | 2 | 1 | 1 | 3 | ↑IgG (n=1) | None | No sx | Mild to moderate | 0 | Formula | Yes | NR | DOL18 |
| Wu et al.58 | China | 5/5/20 | 5 | NR | 2 | 0 | 1 | NR | NR | NR | NR | NR | NR | NR* | ||
| Piersigilli et al., 202063 | Belgium | 5/7/20 | 1 | 1 | 1 | 1 | 2 | NR | Stable | NR | 0 | Expressed BF | Yes | NR | DOL 28 | |
| Pierce-Williams et al.39 | U.S. (NY,NJ, PA,OH) | 5/8/20 | 33 | 24 | 19 | 1 | 1-2 | NR | None | No sx | Severe to critical | NR | NR | NR | NR | NR* |
| Vallejo et al., 202094 | U.S. (NY) | 5/8/20 | 1 | 1 | 1 | 1 | 1 | NR | None | No sx | Critical | 0 | NR | NR | NR | NR* |
| Knight et al., 202030 | U.K. | 5/11/20 | 244 | 144 | 63 | 12 | NR | ↑IgM (n=3) | Mild symptoms | Recovered | Mild to critical | NR | Rec. BF w/ mask | Rec. no | NR | NR* |
| Polónia-Valente et al., 202095 | Portugal | 5/11/20 | 1 | 0 | 0 | 0 | NR | NR | Mild | 0 | Formula | Yes | NR | DOL 3 | ||
| Baergen & Heller, 202096 | U.S. (NY) | 5/12/20 | 21 | 6 | 4 | 0 | NR | NR | Mild to moderate | 0 | NR | NR | NR | NR* | ||
| Taghizadieh et al., 202097 | Iran | 5/13/20 | 1 | 1 | 1 | 0 | NR | NR | Severe | NR | NR | NR | NR | NR* | ||
| Kirtsman et al., 202062 | Canada | 5/14/20 | 1 | 1 | 1 | 1 | 3 | NR | Mild symptoms | Recovered | Moderate | 0 | BF with mask | No | NR | DOL 30 |
| Dória et al., 202098 | Portugal | 5/15/20 | 10 | 6 | 0 | 0 | NR | NR | Asx to mild | 0 | NR | NR | NR | NR* | ||
| Mehta et al., 202035 | U.S. (NJ) | 5/16/20 | 2 | 2 | 2 | 1 | NR | NR | None | No sx | Critical | 2 | Formula | Yes | NR | NR* |
| Patanè et al., 202045 | Italy | 5/18/20 | 22 | NR | NR | 2 | 2-3 | NR | None | No sx | Mild | NR | Some BF, some formula | No | NR | NR* |
| London et al., 202099 | U.S. (NY) | 5/19/20 | 48 | 22 | 9 | 0 | NR | NR | Asx to moderate | NR | NR | NR | NR* | |||
| Joudi et al., 2020100 | U.S. (CA) | 5/20/20 | 1 | 0 | 0 | 0 | NR | NR | Mild | 0 | BF with mask | No | NR | DOL 2 | ||
| Qadri et al., 2020101 | U.S. (MI) | 5/20/20 | 16 | 4 | 1 | 0 | 1 | NR | Asx to severe | 0 | NR | Yes | NR | DOL 7 | ||
| Dumitriu et al.**31 | U.S. (NY) | In press | 101 | 46 | 11 | 2 | 1-4 | NR | None | No sx | Asx to critical | 0 | BF | No | No | DOL25 |
| Total: | 836 | 501 | 185 | 35 | 6 |
a
Abbreviations and symbols used in table: NR = not reported, DOL = day of life, Rec. = recommended, U.S. = United States, U.K. = United Kingdom, SOB = shortness of breath, sx = symptoms, asx = asymptomatic, BF = breastfeeding, neg = negative, wk(s) = week(s), mo = month,↑= elevated, * = presumed immediate postnatal period only, ** = manuscript in press.
b
Red highlighted rows represent studies with SARS-CoV-2-positive newborns.